Rosenbaum R S, Park M C, Fleischmann J
Department of Urology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Urology. 1996 Feb;47(2):208-11. doi: 10.1016/S0090-4295(99)80418-X.
This investigation attempted to determine whether the degree of fibronectin expression in the bladders of patients with invasive transitional cell carcinoma correlated with their clinical response to intravesical bacille Calmette-Guerin (BCG) therapy.
Following transurethral resection of all invasive disease, 13 patients with Stages T2-T4 bladder cancer were administered intravesical BCG (fo 6 weeks followed by monthly instillations). Fibronectin expression in the patients' resected tumors and normal mucosa was determined by immunohistochemical staining techniques. Minimum disease-free follow-up was 60 months.
Only 1 of 13 patients had neither local nor systemic disease recurrence; 10 of 13 patients developed systemic disease and 7 patients died from metastases. Fibronectin expression was not correlated with the clinical response to BCG.
Intravesical BCG therapy for the treatment of muscle invasive transitional cell carcinoma of the bladder is ineffective. Fibronectin expression in the bladder of patients with invasive disease is variable and does not correlate significantly with the clinical response to BCG therapy.
本研究试图确定浸润性移行细胞癌患者膀胱中纤连蛋白的表达程度是否与其对膀胱内卡介苗（BCG）治疗的临床反应相关。
在经尿道切除所有浸润性病变后，对13例T2 - T4期膀胱癌患者进行膀胱内BCG治疗（为期6周，随后每月灌注一次）。通过免疫组织化学染色技术测定患者切除肿瘤和正常黏膜中的纤连蛋白表达。最短无病随访期为60个月。
13例患者中只有1例既无局部也无全身疾病复发；13例患者中有10例发生全身疾病，7例患者死于转移。纤连蛋白表达与对BCG的临床反应无关。
膀胱内BCG治疗肌肉浸润性膀胱移行细胞癌无效。浸润性疾病患者膀胱中的纤连蛋白表达各不相同，与对BCG治疗的临床反应无显著相关性。
